Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rilonacept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Rilonacept. Displaying page 1 of 1.
    EudraCT Number: 2008-007762-39 Sponsor Protocol Number: IL1T-GA-0816 Start Date*: 2009-09-23
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy
    Medical condition: Gout flare
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064900 Gout flare LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005726-30 Sponsor Protocol Number: CURES-IL1T-OT-1236 Start Date*: 2014-04-28
    Sponsor Name:Charité - Universitätsmedizin
    Full Title: A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)
    Medical condition: cold contact urticaria (CCU)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007784-16 Sponsor Protocol Number: IL1T-GA-0815 Start Date*: 2010-01-05
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy.
    Medical condition: Gout flares
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064900 Gout flare LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002719-87 Sponsor Protocol Number: KPL-914-C002 Start Date*: 2019-05-02
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd
    Full Title: Phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of Rilonacept treatment in subjects with recurrent pericarditis –...
    Medical condition: Recurrent pericarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000996 Acute pericarditis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004290-97 Sponsor Protocol Number: ACCILTRA1 Start Date*: 2008-12-19
    Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
    Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle...
    Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016859-22 Sponsor Protocol Number: CACZ885D2307 Start Date*: 2013-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younge...
    Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068850 Cryopyrin associated periodic syndrome LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) Outside EU/EEA IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005479-82 Sponsor Protocol Number: CACZ885G2301 Start Date*: 2009-06-12
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio doble ciego, randomizado, controlado con placebo, con diseño de retirada en la prevención de brotes con canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica y manifes...
    Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) BE (Completed) DE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) AT (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005476-27 Sponsor Protocol Number: CACZ885G2305 Start Date*: 2009-05-14
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio randomizado, doble ciego, controlado con placebo, a dosis única para evaluar la eficacia inicial de canakinumab (ACZ885) respecto a los Criterios ACR 30 Pediátricos Adaptados en pacientes c...
    Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) DE (Completed) BE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003527-57 Sponsor Protocol Number: CACZ885DTR01 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
    Medical condition: Familial Mediterranean Fever
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003522-13 Sponsor Protocol Number: CACZ885D2204 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resist...
    Medical condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004867-29 Sponsor Protocol Number: CACZ885G2306 Start Date*: 2014-09-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and saf...
    Medical condition: Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) ES (Completed) HU (Completed) DE (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003054-92 Sponsor Protocol Number: CACZ885G2402 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)
    Medical condition: Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001323-23 Sponsor Protocol Number: CH/2013/4247 Start Date*: 2015-07-03
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis.
    Medical condition: Juvenile Idiopathic Arthritis with Associated Uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011593-15 Sponsor Protocol Number: WA19977 Start Date*: 2009-08-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab ...
    Medical condition: Polyarticular-course juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) NL (Not Authorised) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000435-33 Sponsor Protocol Number: NP25737 Start Date*: 2015-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA)
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 23:28:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA